---  
layout: startup_page  
title: "PAQ Therapeutics"  
id: "paqtx.com"  
permalink: "/paqtherapeuticspaqtx.com05072025/"  
website: "https://www.paqtx.com/"  
funding_round: "Series B"  
funding_amount: "$39M"  
investors: "Bayland Capital, MRL Ventures Fund (MRLV), Johnson & Johnson Innovation â€“ JJDC, Inc., LAV Fund, BioTrack Capital, Sherpa Health Partners"  
about: "PAQ Therapeutics is a clinical-stage biotechnology company focused on developing best- and first-in-class KRAS degraders to treat lethal cancers without effective treatment options. Their lead asset, PT0253, is a potent and selective degrader of KRAS G12D, with the first patient dosed in a Phase 1 clinical study in Q1 2025. The company's approach aims to overcome limitations of existing KRAS inhibitors, providing more effective and durable treatments."  
markets: "Biotech, Oncology, Health Care, Therapeutics"  
hq: "Burlington, Massachusetts, United States"  
founded_year: "2020"  
linkedin: "https://www.linkedin.com/company/paq-therapeutics"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/paq-therapeutics"  
pitchbook: "https://pitchbook.com/profiles/company/470023-48"  

date_display: "07-May-2025"  
date: "2025-05-07"

# SEO Optimization  
meta_title: "PAQ Therapeutics - Series B Funding ($39M)"  
meta_description: "PAQ Therapeutics, PAQ Therapeutics is a clinical-stage biotechnology company focused on developing best- and first-in-class KRAS degraders to treat lethal cancers witho..."  
meta_keywords: "PAQ Therapeutics, Biotech, Oncology, Health Care, Therapeutics, Series B funding"  
canonical_url: "https://startup.projectstartups.com/paqtherapeuticspaqtx.com05072025/"  
---